---
title: "BLRX.US (BLRX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BLRX.US/news.md"
symbol: "BLRX.US"
name: "BLRX.US"
parent: "https://longbridge.com/en/quote/BLRX.US.md"
datetime: "2026-05-19T17:25:07.234Z"
locales:
  - [en](https://longbridge.com/en/quote/BLRX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BLRX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BLRX.US/news.md)
---

# BLRX.US (BLRX.US) — Related News

### [BioLineRx starts Phase 1/2a trial of GLIX1 in recurrent glioblastoma](https://longbridge.com/en/news/286900261.md)
*2026-05-19T11:04:52.000Z*
> BioLineRx has initiated a Phase 1/2a trial of GLIX1 for recurrent glioblastoma, supported by preclinical data showing an

### [BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts | BLRX Stock News](https://longbridge.com/en/news/286899389.md)
*2026-05-19T03:00:53.000Z*
> BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across M

### [12 Health Care Stocks Moving In Monday's After-Market Session](https://longbridge.com/en/news/286822962.md)
*2026-05-18T21:05:47.000Z*
> In Monday's after-market session, BioLine Rx (BLRX) gained 12.5% to $3.11, while CDT Equity (CDT) rose 9.35% to $1.64. N

### [](https://longbridge.com/en/news/284437535.md)
*2026-04-28T18:41:45.000Z*
> BioLineRx shares are trading higher after the company announces that the first patient has been dosed in its Phase 1/2A 

### [Hemispherian begins Phase I/IIa trial of GLIX1 for GBM](https://longbridge.com/en/news/282305329.md)
*2026-04-09T09:47:05.000Z*
> Hemispherian has launched a Phase I/IIa trial for its oral small molecule GLIX1, targeting recurrent and progressive gli

### [Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma | BLRX Stock News](https://longbridge.com/en/news/281985478.md)
*2026-04-07T22:30:58.000Z*
> Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma | BLRX Stock News

### [BLRX: Full year 2025 results](https://longbridge.com/en/news/280217686.md)
*2026-03-23T21:27:16.000Z*
> BioLineRx Ltd. (NASDAQ: BLRX) reported its 2025 financial results, revealing license revenues of $1.2 million and a net 

### [Options Volatility and Implied Earnings Moves Today, March 23, 2026](https://longbridge.com/en/news/280158602.md)
*2026-03-23T12:06:18.000Z*
> Today, major companies including Bioline RX Ltd (BLRX), Lithium Argentina (LAR), and MBX Biosciences (MBX) are set to re

### [BioLineRx Reports 2025 Financial Results and Provides Corporate Update | BLRX Stock News](https://longbridge.com/en/news/280147189.md)
*2026-03-23T03:00:41.000Z*
> BioLineRx Reports 2025 Financial Results and Provides Corporate Update | BLRX Stock News